contador gratuito PATIENT73-

Clinical trials


By start date

since

until

By recruitment date

since

until

By end date

since

until


Due to illness
By entity
By state
By country


By Sponsor


Search by name





    Trail Sponsor Illness



  Phase I Clinical Study of Dose-escalation Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of Recombinant Anti-FGFR Human-mouse Chimeric Monoclonal Antibody Injection BK011 in Patients with Advanced Malignant Solid Tumors

Start: 18/5/2022
Recruitment:
Final:

Status: In progress
Zhejiang Newind Biotechnology Co. Esophageal Neoplasms; Stomach Neoplasms






  Phase I/II Clinical Study of Mitoxantrone Hydrochloride Liposomes in Combination With Gemcitabine, Dexamethasone, and Cisplatin in Relapsed/Refractory Peripheral T-cell Lymphoma

Start: 1/5/2022
Recruitment:
Final:

Status: In progress
Peking Union Medical College Hospital, CAMS CSPC Pharmaceutical Group Co./CSPC Ouyi Pharmaceutical Co. Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral






  Single arm and single center clinical study on safety, tolerance and efficacy of GC101 injection in patients with type 1 spinal muscular atrophy

Start: 16/2/2022
Recruitment:
Final:

Status: In progress
(Other Hospital/Academic/Medical Center) GeneCradle Spinal Muscular Atrophy






  Clinical Study on the Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer

Start: 2/4/2021
Recruitment:
Final:

Status: In progress
Shanghai Biomed-Union Biotechnology Co. Pancreatic Neoplasms






  Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for Injection in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma

Start: 26/6/2022
Recruitment:
Final:

Status: In progress
CASI Pharmaceuticals {EntreMed} (Other Hospital/Academic/Medical Center) Multiple Myeloma; Neoplasms, Plasma Cell






  A Phase I study of ZS801 injection, an rAAV gene therapy drug of Sichuan Zhishan Weixin Biotechnology Co., Ltd., in hemophilia B subjects.

Start: 1/1/1900
Recruitment:
Final:

Status: In progress
Sichuan Zhishan Weixin Biotechnology Co. Blood Coagulation Disorders; Hemophilia B; Hemostatic Disorders






  A Phase I Clinical Study of CD70-targeting CAR-T Therapy in the Treatment of Advanced/Metastatic Renal Cell Carcinoma

Start: 31/12/2021
Recruitment:
Final:

Status: In progress
Chongqing Precision Biotech Co. Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Neoplasm Metastasis; Wilms Tumor






  This is a Phase I Clinical Study to Evaluate the Safety and Efficacy of CAR-T Infusion Preparation in the Treatment of CD19-positive Relapsed/Refractory Non-Hodgkin Lymphoma

Start: 6/9/2021
Recruitment:
Final:

Status: In progress
Chongqing Precision Biotech Co. Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin






  An Open, Single-armed, Phase I Study to Evaluate the Safety and Efficacy Using Autologous TIL in Patients With Advanced Malignant Solid Tumors

Start: 14/6/2022
Recruitment:
Final:

Status: In progress
Shanghai Gencells Therapeutics Co. Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Head and Neck Neoplasms; Melanoma; Neoplasms; Uterine Cervical Neoplasms






  A Phase I Clinical Study of Anti-CEA CAR-T Therapy in the Treatment of CEA-positive Advanced Malignant Solid Tumors

Start: 10/9/2021
Recruitment:
Final:

Status: In progress
Chongqing Precision Biotech Co. Colorectal Neoplasms; Esophageal Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Recurrence; Stomach Neoplasms



1